CAN EARLY LASER THERAPY DELAY DISEASE PROGRESSION?

Retinal Physician, September, 2009
Read more

STUDY SHOWS ELLEX 2RT SAFE, EFFECTIVE FOR TREATING DIABETIC MACULAR EDEMA

OSN SuperSite, November, 2008
Read more

IRV ARONS' JOURNAL

Irving Arons spent more than 30 years as a consultant to the ophthalmology industry, and more than 20 years as a medical laser industry consultant before retiring in 2005. Since then, he has continued to follow and comment on notable industry research, events and other topics in his blog, “Irv Aron’s Journal.” Late in 2007, he included a lengthy entry about 2RT research, writing, in part, “In looking further into this technique, I became convinced that, although it was very early in its development, it held the potential to become an important treatment in the armamentarium of retinal physicians."
Read the entire blog entry here.

7 MAY 2010
ELLEX 2RT STUDIES DEMONSTRATE CLINICAL EFFICACY IN TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND DIABETIC RETINOPATHY

Ellex announced today major positive clinical results for its world leading laser Retina Regeneration Therapy (Ellex 2RT™) for the treatment of Age-related Macular Degeneration (AMD) and Diabetic Retinopathy (DR), two conditions that usually result in irreversible blindness for sufferers.
Read more

12 APR 2010
ELLEX SECURES SUBLICENCE AGREEMENT FOR ELLEX 2RT

Ellex announced today that it has sublicensed Patent No. 5,549,596, effectively enabling the Company to bring Ellex 2RT™ technology to market in the US.
Read more

10 NOV 2008
ELLEX ANNOUNCES SIX-MONTH RESULTS ON RETINA REGENERATION THERAPY

Ellex today announced the six-month clinical study results for the groundbreaking treatment Retina Regeneration Therapy (Ellex 2RT™).  
Read more

1 NOV 2007
ELLEX ANNOUNCES NEW RETINA REGENERATION THERAPY TO BE PRESENTED AT THE AAO

Ellex today announced that the initial results of treating patients with Retina Regeneration Therapy (Ellex 2RT™) will be presented by Peter Hamilton MD, FRCOph at the annual meeting of the American Academy of Ophthalmology.
Read more

Selective Retinal Pigment Epithelial Treatment for Diabetic Macular Oedema: Six Month Results
Professor John Marshall, PhD, Euretina 2009.

Sequestration of MMPs 2&9 by Ageing Human Bruch's Membrane: Relevance to Functional Deterioration
A. Kumar; A. El-Osta; A.A. Hussain; J. Marshall.
ARVO Presentation Abstract - Tuesday 5 May, 2009, 1:45pm - 3:30pm

Effect of Sub-Threshold Laser Energy (Ellex 2RT) on the Matrix Metalloproteinase (MMP) Release Profile of RPE and the Diffusional Status of Underlying Bruch's Membrane
J. Zhang; Y. Sun; A. Hussain; J. Marshall.
ARVO Presentation Abstract - Tuesday 5 May, 2009, 1:45pm - 3:30pm

Photoregeneration Therapy: Treatment of Diabetic Maculopathy. Six Months’ Clinical Trial Results
Professor John Marshall, PhD, American Academy of Ophthalmology (AAO) 2008.

WEBINARS

Photoregeneration Therapy: Treatment of Diabetic Maculopathy. Six Months Clinical Trial Results
Professor John Marshall, PhD, American Academy of Ophthalmology (AAO) 2008.

After more than a year of clinical research, the much-anticipated follow-up results are available regarding Ellex 2RT (Retina Regeneration Therapy) and the treatment of diabetic macula edema.

"Photoregeneration" - Tissue Interaction and Mechanisms of Action
Professor John Marshall, PhD, American Academy of Ophthalmology (AAO) 2007.

Professor Marshall will explain the mechanisms of action behind Selective Laser Trabeculoplasty and their relationship to emerging non-thermal therapies for restoring retinal function.